MedTrace Logo

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

NCT02639130 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2016-08-16

No results posted yet for this study

Summary

To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.

Conditions

Interventions

DRUG

Exendin [9-39]

Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent

DRUG

Placebo

Placebo infusion as challenge agent

Sponsors & Collaborators

  • Diabeteszentrum Bad Lauterberg im Harz

    lead OTHER

Principal Investigators

  • Michael A. Nauck, Prof. · Diabeteszentrum Bad Lauterberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02639130 on ClinicalTrials.gov